Epoxyeicosatrienoic acids: Novel mediators of cardioprotection

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 2, 2010, Pages 112-119

  Nithipatikom, Kasem ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acute myocardial infarction; Brain natriuretic peptide; Ischemia reperfusion injury; Ischemic heart disease

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO)DODENOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO)DODENOIC ACID BUTYL ESTER; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CHLORAMPHENICOL; CIMETIDINE; CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID; PROTECTIVE AGENT; SULFAPHENAZOLE; UNCLASSIFIED DRUG; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; CELL FUNCTION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; ISOLATED HEART; METABOLITE; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; STUNNED HEART MUSCLE; ANIMAL; HEART INFARCTION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; MITOCHONDRIA; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; NATRIURETIC PEPTIDE, BRAIN;

EID: 77951884617     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409358408     Document Type: Review

References (32)

1. Capdevila JH, Falck JR, Estabrook RW Cytochrome P450 and the arachidonate cascade. FASEB J. 1992 ; 6 (2). 731-736.
2. Seubert JM, Zeldin DC, Nithipatikom K., et al. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2007 ; 82 (1-4). 50-59.
3. Moffat MP, Ward CA, Bend JR, et al. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol (Heart and Circulatory). 1993 ; 264 (4). H1154 - H1160.
4. Wu S., Moomaw W., Tomer KB, Falck JR, Zeldin DC Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996 ; 271 (7). 3460-3468.
5. Wu S., Chen W., Murphy E., et al. Molecular cloning, expression and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997 ; 272 (19). 12551-12559.
6. Campbell WB, Gebremedhin D., Pratt PF, Harder DR Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996 ; 78 (3). 415-423.
7. Seubert J., Yang B., Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathways. Circ Res. 2004 ; 95 (5). 506-514.
8. Seubert J., Sinal CJ, Graves J., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006 ; 99 (4). 442-450.
9. Gauthier KM, Deeter C., Krishna M., et al. 14,15-epoxyeicosa5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits emdothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002 ; 90 (9). 1028-1036.
10. Chaudhary KR, Batchu SN, Das D., et al. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved postischemic recovery of heart contractile function. Cardiovasc Res. 2009 ; 83: 362-370.
11. Batchu SN, Law E., Brocks DR, Falck JR, Seubert JM Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol. 2009 ; 46 (1). 67-74.
12. Ke Q., Xiao YF, Bradbury JA, et al. Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice. Mol Pharmacol. 2007 ; 72 (4). 1063-1073.
13. Javadov S., Karmazyn M., Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther. 2009 ; 330 (3). 670-678.
14. Katragadda D., Batchu SN, Cho WJ, Chaudhary KR, Falck JR, Seubert JM Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J Mol Cell Cardiol. 2009 ; 46 (6). 867-875.
15. Nithipatikom K., DiCammelli RF, Kohler S. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs. Anal Biochem. 2001 ; 292 (1). 115-124.
16. Gross GJ, Hsu A., Falck JR, Nithipatikom K. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol. 2007 ; 42 (3). 687-691.
17. Granville DJ, Tashakkor B., Takeuchi C., et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A. 2004 ; 101 (5). 1321-1326.
18. Nithipatikom K., Gross ER, Endsley MP, et al. Inhibition of cytochrome P450Ï-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 2004 ; 95: 65-61.
19. Nithipatikom K., Moore JM, Isbell MA, Falck JR, Gross GJ Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol. 2006 ; 291 (2). H537 - H542.
20. Gross GJ, Gauthier KM, Moore J., et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008 ; 294 (6). H2838 - H2844.
21. Gross GJ, Gauthier KM, Moore J., Campbell WB, Falck JR, Nithipatikom K. Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in the dog. Am J Physiol Heart Circ Physiol. 2009 ; 297 (1). H47 - H42.
22. Motoki A., Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia/reperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008 ; 295 (5). H2128 - H2134.
23. Xu D., Li N., He Y., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 2006 ; 103 (49). 18733-18738.
24. Li N., Liu JY, Timofeyev V., et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol. 2009 ; 47 (6). 835-845.
25. Spector AA, Norris AW Action of epoxyeicosatrienoic acids on cellular function. Am J Cell Physiol. 2007 ; 292 (3). C996C1012.
26. Hausenloy DJ, Yellon DM New directions for protecting the heart against ischemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004 ; 61: 448-460.
27. Dhanasekaran A., Al-Saghir R., Lopez B., et al. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol. 2006 ; 291 (2). H517 - H531.
28. Bodiga S., Zhang R., Jacobs DE, et al. Protective effect of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J Mol Cell Cardiol. 2009 ; 46: 978-988.
29. Yang S., Lin L., Chen JX, et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol. 2007 ; 293 (1). H142 - H151.
30. Yang W., Venugopal RT, Anjaiah S., et al. Characterization of epoxyeicosatrienoic acid binding site in U37 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa8Z-enoic acid. J Pharmacol Exp Ther. 2008 ; 324: 1019-1027.
31. Gross GJ, Nithipatikom K. Soluble epoxide hydrolase: a new target for cardioprotection. Curr Opin Investig Drugs. 2009 ; 10 (3). 253-258.
32. Imig JD, Hammock BD Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discovery. 2009 ; 8 (10). 704-705.